Tao Li, Yang Jin-Kun, Gu Ying, Zhou Xin, Zhao Ai-Guang, Zheng Jian, Zhu Ying-Jie
Li Tao, Jin-Kun Yang, Ying Gu, Ai-Guang Zhao, Jian Zheng, Ying-Jie Zhu, Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
World J Gastroenterol. 2015 Jan 28;21(4):1125-39. doi: 10.3748/wjg.v21.i4.1125.
To examine the effect of Weichang'an (WCA) and 5-fluorouracil (5-FU) on colorectal tumor and hepatic metastasis in a mouse model.
Quantitative determination of hesperidin, the effective component in WCA decoction, was performed using HPLC. In vitro cytotoxicity of WCA was determined by treating HCT-116 cells with WCA diluents or serum extracted from rats that received WCA by oral gavage for 1 wk and MTT assays. Forty-eight nude mice received cecum implantation with tumor blocks subcutaneously amplified from human colon cancer cell line HCT-116. Mice were randomly divided into four treatment groups: control (CON), WCA, 5-FU and combination (WCA+5-FU). Pathological examination of tumors consisted of tissue sectioning and hematoxylin and eosin staining. Tumor weight and size were measured, and the number of metastatic lesions was counted. Serum carcinoembryonic antigen (CEA) level was determined by ELISA. The expression levels of tumor genesis and metastasis-related proteins β-catenin and matrix metalloproteinase (MMP)-7 were measured by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR), immunohistochemistry and immunoblotting. Cell fractionation was used to investigate intracellular distribution of β-catenin.
Parenchymal tumors were palpable in the abdomens of nude mice 2 wk post-implantation and orthotopic tumor formation rate was 100% in all groups. 5-FU treatment alone significantly decreased tumor weight compared to the CON group (1.203±0.284 g vs 1.804±0.649 g, P<0.01). WCA treatment alone reduced the rate of metastasis (50% vs 100%, P<0.05). Combination treatment of WCA+5-FU was the most effective, reducing the tumor weight (1.140±0.464 g vs 1.804±0.649 g, P<0.01) and size (1493.438±740.906 mm3 vs 2180.259±816.556 mm3, P<0.05), the rate of metastases (40% vs 100%, P<0.01), and serum CEA levels (31.263±7.421 μg/L vs 43.040±11.273 μg/L, P<0.05). Expression of β-catenin and MMP-7 was decreased in drug-treated groups compared to controls, as detected using real-time quantitative RT-PCR, immunohistochemistry and immunoblotting, respectively. Cell fractionation assays revealed that nuclear translocation of β-catenin was reduced by WCA and/or 5-FU treatments.
Combination of WCA with 5-FU significantly inhibited colon tumor growth and hepatic metastases. Decreased expression of β-catenin and MMP-7 may be important.
在小鼠模型中研究胃肠安(WCA)和5-氟尿嘧啶(5-FU)对结直肠癌及肝转移的影响。
采用高效液相色谱法对胃肠安汤剂中的有效成分橙皮苷进行定量测定。通过用胃肠安稀释剂或从经口灌胃给予胃肠安1周的大鼠血清处理HCT-116细胞并进行MTT试验,测定胃肠安的体外细胞毒性。48只裸鼠接受皮下接种从人结肠癌细胞系HCT-116扩增而来的肿瘤块的盲肠植入。小鼠被随机分为四个治疗组:对照组(CON)、胃肠安组、5-氟尿嘧啶组和联合治疗组(胃肠安+5-氟尿嘧啶)。肿瘤的病理检查包括组织切片及苏木精-伊红染色。测量肿瘤重量和大小,并计数转移灶数量。采用酶联免疫吸附测定法测定血清癌胚抗原(CEA)水平。通过实时定量逆转录聚合酶链反应(RT-PCR)、免疫组织化学和免疫印迹法测量肿瘤发生和转移相关蛋白β-连环蛋白和基质金属蛋白酶(MMP)-7的表达水平。采用细胞分级分离法研究β-连环蛋白的细胞内分布。
植入后2周,裸鼠腹部可触及实质性肿瘤,所有组的原位肿瘤形成率均为100%。与对照组相比,单独使用5-氟尿嘧啶治疗显著降低了肿瘤重量(1.203±0.284 g对1.804±0.649 g,P<0.01)。单独使用胃肠安治疗降低了转移率(50%对100%,P<0.05)。胃肠安+5-氟尿嘧啶联合治疗最有效,降低了肿瘤重量(1.140±0.464 g对1.804±0.649 g,P<0.01)和大小(1493.438±740.906 mm³对2180.259±816.556 mm³,P<0.05)、转移率(40%对100%,P<0.01)以及血清CEA水平(31.263±7.421 μg/L对43.040±11.273 μg/L,P<0.05)。与对照组相比,分别使用实时定量RT-PCR、免疫组织化学和免疫印迹法检测发现,药物治疗组中β-连环蛋白和MMP-7的表达降低。细胞分级分离试验显示,胃肠安和/或5-氟尿嘧啶治疗减少了β-连环蛋白的核转位。
胃肠安与5-氟尿嘧啶联合使用可显著抑制结肠肿瘤生长和肝转移。β-连环蛋白和MMP-7表达降低可能起重要作用。